References
- Ministry for Health, Welfare and Family Affairs, National Cancer Center. Annual report of cancer incidence (2005) and survival (1993-2005) in Korea. 2008
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
- Korean Statistical Information Services
- Ministry for Health and Welfare, National Cancer Center. Annual report of cancer incidence and survivalin Korea. 2003
- Park JW. National cancer screening program. Korean J Hepatol 2002;8(Suppl 3):S16-S19
- Park JW. Practice guideline for diagnosis and treatment of hepatocellular carcinoma. Korean J Hepatol 2004;10:88-98
- Agency for Healthcare Research Quality USPSTF. Ranking evidence about the effectiveness of treatments or screening
- Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42:1208-1236 https://doi.org/10.1002/hep.20933
- Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:417-422
- Trevisani F, De NS, Rapaccini G, Farinati F, Benvegnu L, Zoli M, et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002;97:734-744 https://doi.org/10.1111/j.1572-0241.2002.05557.x
- Jain D. Diagnosis of hepatocellular carcinoma: fine needle aspiration cytology or needle core biopsy. J Clin Gastroenterol 2002;35(Suppl 2):S101-S108 https://doi.org/10.1097/00004836-200211002-00006
- Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso JR, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008;47:97-104 https://doi.org/10.1002/hep.21966
- Trevisani F, D’Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 2001;34:570-575 https://doi.org/10.1016/S0168-8278(00)00053-2
- Chen DS, Sung JL, Sheu JC, Lai MY, How SW, Hsu HC, et al. Serum alpha-fetoprotein in the early stage of human hepatocellular carcinoma. Gastroenterology 1984;86:1404-1409
- Hayashi K, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, et al. Usefulness of measurement of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein as a marker of prognosis and recurrence of small hepatocellular carcinoma. Am J Gastroenterol 1999;94: 3028-3033
- Taketa K, Endo Y, Sekiya C, Tanikawa K, Koji T, Taga H, et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993;53:5419-5423
- Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, et al. Sensitivity and specificity of desgamma- carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol 2006;101:2038-2043 https://doi.org/10.1111/j.1572-0241.2006.00681.x
- Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. Hepatology 2003;37:1114-1121 https://doi.org/10.1053/jhep.2003.50195
- Ishizuka H, Nakayama T, Matsuoka S, Gotoh I, Ogawa M, Suzuki K, et al. Prediction of the development of hepato-cellular-carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity. Intern Med 1999;38:927-931 https://doi.org/10.2169/internalmedicine.38.927
- Giardina MG, Matarazzo M, Morante R, Lucariello A, Varriale A, Guardasole V, et al. Serum alpha-L-fucosidase activity and early detection of hepatocellular carcinoma: a prospective study of patients with cirrhosis. Cancer 1998; 83:2468-2474 https://doi.org/10.1002/(SICI)1097-0142(19981215)83:12<2468::AID-CNCR9>3.0.CO;2-Y
- Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125:89-97 https://doi.org/10.1016/S0016-5085(03)00689-9
- Kudo M, Okanoue T; Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007;72(Suppl 1): 2-15
- Makuuchi M, Kokudo N, Arii S, Futagawa S,Kaneko S, Kawasaki S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008;38:37-51 https://doi.org/10.1111/j.1872-034X.2007.00216.x
- Kim KA, Lee JS, Jung ES, Kim JY, Bae WK, Kim NH, et al. Usefulness of serum alpha-fetoprotein (AFP) as a marker for hepatocellular carcinoma (HCC) in hepatitis C virus related cirrhosis: analysis of the factors influencing AFP elevation without HCC development. Korean J Gastroenterol 2006;48:321-326
- Kim MJ, Bae KW, Seo PJ, Jeong IK, Kim JH, Lee BH, et al. Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma: using ROC curve. Korean J Hepatol 2006;12:404-411
- Yoon YJ, Han KH, Kim C, Chon CY, Moon YM, Han CH, et al. Clinical efficacy of serum PIVKA-II in the diagnosis and follow up after treatment of hepatocellular carcinoma. Korean J Hepatol 2002;8:465-471
- Zacherl J, Pokieser P, Wrba F, Scheuba C, Prokesch R, Zacherl M, et al. Accuracy of multiphasic helical computed tomography and intraoperative sonography in patients undergoing orthotopic liver transplantation for hepatoma: what is the truth? Ann Surg 2002;235:528-532 https://doi.org/10.1097/00000658-200204000-00011
- Krinsky GA, Lee VS, Theise ND, Weinreb JC, Morgan GR, Diflo T, et al. Transplantation for hepatocellular carcinoma and cirrhosis: sensitivity of magnetic resonance imaging. Liver Transpl 2002;8:1156-1164 https://doi.org/10.1053/jlts.2002.35670
- Kim SH, Choi BI, Lee JY, Kim SJ, So YH, Eun HW, et al. Diagnostic accuracy of multi-/single-detector row CT and contrast-enhanced MRI in the detection of hepatocellular carcinomas meeting the milan criteria before liver transplantation. Intervirology 2008;51(Suppl 1):52-60
- Colli A, Fraquelli M, Casazza G, Massironi S, Colucci A, Conte D, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006;101:513-523 https://doi.org/10.1111/j.1572-0241.2006.00467.x
- Piscaglia F, Bolondi L. Recent advances in the diagnosis of hepatocellular carcinoma. Hepatol Res 2007;37(Suppl 2): S178-S192 https://doi.org/10.1111/j.1872-034X.2007.00183.x
- Kojiro M, Roskams T. Early hepatocellular carcinoma and dysplastic nodules. Semin Liver Dis 2005;25:133-142 https://doi.org/10.1055/s-2005-871193
- Matsui O. Detection and characterization of hepatocellular carcinoma by imaging. Clin Gastroenterol Hepatol 2005;3 (Suppl 2):S136-S140 https://doi.org/10.1016/S1542-3565(05)00707-X
- Park JW, An M, Choi JI,Kim YI, Kim SH, Lee WJ, et al. Accuracy of clinical criteria for the diagnosis of hepatocellular carcinoma without biopsy in a Hepatitis B virusendemic area. J Cancer Res Clin Oncol 2007;133:937-943 https://doi.org/10.1007/s00432-007-0232-y
- Park JW, Kim JH, Kim SK, Kang KW, Park KW, Choi JI, et al. A prospective evaluation of 18F-FDG and 11Cacetate PET/CT for detection of primary and metastatic hepatocellular carcinoma. J Nucl Med 2008;49: 1912-1921 https://doi.org/10.2967/jnumed.108.055087
- Ueno S, Tanabe G, Nuruki K, Hamanoue M, Komorizono Y, Oketani M, et al. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res 2002;24:395-403 https://doi.org/10.1016/S1386-6346(02)00144-4
- Lang H, Sotiropoulos GC, Domland M, Fruhauf NR, Paul A, Husing J, et al. Liver resection for hepatocellular carcinoma in non-cirrhotic liver without underlying viral hepatitis. Br J Surg 2005;92:198-202 https://doi.org/10.1002/bjs.4763
- Capussotti L, Muratore A, Massucco P, Ferrero A, Polastri R, Bouzari H. Major liver resections for hepatocellular carcinoma on cirrhosis: early and long-term outcomes. Liver Transpl 2004;10(Suppl 1):S64-S68 https://doi.org/10.1002/lt.20035
- Poon RT, Fan ST, Lo CM, Ng IO, Liu CL, Lam CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001;234:63-70 https://doi.org/10.1097/00000658-200107000-00010
- Kim JH, Choi DW, Kim SB. Saftey and long-term outcome following major hepatectomy for hepatocellular carcinoma combined with compensated liver cirrhosis. J Korean Surg Soc 2006;70:444-450
- Lee KW. 1000 Cases of surgical resection for hepatocellular carcinoma. Kor J HBP Surgery postgraduate course 1998
- Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-649 https://doi.org/10.1002/bjs.1800600817
- Makuuchi M, Sano K. The surgical approach to HCC: our progress and results in Japan. Liver Transpl 2004;10(Suppl 1):S46-S52 https://doi.org/10.1002/lt.20044
- Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434-1440 https://doi.org/10.1002/hep.510300629
- An M, Park JW, Shin JA, Choi JI, Kim TH, Kim SH, et al. The adverse effect of indirectly diagnosed portal hypertension on the complications and prognosis after hepatic resection of hepatocellular carcinoma. Korean J Hepatol 2006;12:553-561
- Marin D, Di Martino M, Guerrisi A, De Filippis G, Rossi M, Ginanni Corradini S, et al. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT. Radiology 2009;251:85-95 https://doi.org/10.1148/radiol.2511080400
- Koneru B, Teperman LW, Manzarbeitia C, Facciuto M, Cho K, Reich D, et al. A multicenter evaluation of utility of chest computed tomography and bone scans in liver transplant candidates with stages I and II hepatoma. Ann Surg 2005;241:622-628 https://doi.org/10.1097/01.sla.0000157267.27356.80
- Sheth H, Javed SS, Hilson AJ, Buscombe JR, Davidson BR. Radioisotope bone scans in the preoperative staging of hepatopancreatobiliary cancer. Br J Surg 2005;92:203-207 https://doi.org/10.1002/bjs.4805
- Torzilli G, Palmisano A, Del Fabbro D, Marconi M, Donadon M, Spinelli A, et al. Contrast-enhanced intraoperative ultrasonography during surgery for hepatocellular carcinoma in liver cirrhosis: is it useful or useless? A prospective cohort study of our experience. Ann Surg Oncol 2007;14:1347-1355 https://doi.org/10.1245/s10434-006-9278-3
- Zhang K, Kokudo N, Hasegawa K, Arita J, Tang W, Aoki T, et al. Detection of new tumors by intraoperative ultrasonography during repeated hepatic resections for hepatocellular carcinoma. Arch Surg 2007;142:1170-1175 https://doi.org/10.1001/archsurg.142.12.1170
- Kim IS, Lim YS, Yoon HK, Sung KB, Jang MK, Choi WB, et al. The effect of preoperative transarterial chemoembolization on the patient's outcome in resectable hepatocellular carcinoma. Korean J Med 2005;69:614-621
- Wu CC, Ho YZ, Ho WL, Wu TC, Liu TJ, P’eng FK. Preoperative transcatheter arterial chemoembolization for resectable large hepatocellular carcinoma: a reappraisal. Br J Surg 1995;82:122-126 https://doi.org/10.1002/bjs.1800820141
- Farges O, Belghiti J, Kianmanesh R, Regimbeau JM, Santoro R, Vilgrain V, et al. Portal vein embolization before right hepatectomy: prospective clinical trial. Ann Surg 2003;237:208-217 https://doi.org/10.1097/00000658-200302000-00010
- Tanaka H, Hirohashi K, Kubo S, Shuto T, Higaki I, Kinoshita H. Preoperative portal vein embolization improves prognosis after right hepatectomy for hepatocellular carcinoma in patients with impaired hepatic function. Br J Surg 2000;87:879-882 https://doi.org/10.1046/j.1365-2168.2000.01438.x
- Hanazaki K, Kajikawa S, Shimozawa N, Matsushita A, Machida T, Shimada K, et al. Perioperative blood transfusion and survival following curative hepatic resection for hepatocellular carcinoma. Hepatogastroenterology 2005;52:524-529
- Tanaka K, Shimada H, Matsuo K, Nagano Y, Endo I, Togo S. Intra-operative blood loss predicts complications after a second hepatectomy for malignant neoplasms. Ann Surg Oncol 2007;14:2668-2677 https://doi.org/10.1245/s10434-007-9427-3
- Tsujita E, Taketomi A, Kitagawa D, Itoh S, Harimoto N, Gion T, et al. Selective hepatic vascular exclusion for the hepatic resection of HCC. Hepatogastroenterology 2007;54: 527-530
- Eguchi S, Kanematsu T, Arii S, Okazaki M, Okita K, Omata M, et al. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery 2008;143: 469-475 https://doi.org/10.1016/j.surg.2007.12.003
- Suh KS. Systematic hepatectomy for small hepatocellular carcinoma in Korea. J Hepatobiliary Pancreat Surg 2005;12: 365-370 https://doi.org/10.1007/s00534-005-1002-3
- Wakai T, Shirai Y, Sakata J, Kaneko K, Cruz PV, Akazawa K, et al. Anatomic resection independently improves long-term survival in patients with T1-T2 hepatocellular carcinoma. Ann Surg Oncol 2007;14:1356-1365 https://doi.org/10.1245/s10434-006-9318-z
- Shi M, Zhang CQ, Zhang YQ, Liang XM, Li JQ. Micrometastases of solitary hepatocellular carcinoma and appropriate resection margin. World J Surg 2004;28: 376-381 https://doi.org/10.1007/s00268-003-7308-x
- Tralhao JG, Kayal S, Dagher I, Sanhueza M, Vons C, Franco D. Resection of hepatocellular carcinoma: the effect of surgical margin and blood transfusion on long-term survival. Analysis of 209 consecutive patients. Hepatogastroenterology 2007;54:1200-1206
- Ellsmere J, Kane R, Grinbaum R, Edwards M, Schneider B, Jones D. Intraoperative ultrasonography during planned liver resections: why are we still performing it? Surg Endosc 2007;21:1280-1283 https://doi.org/10.1007/s00464-006-9192-6
- Chen HY, Juan CC, Ker CG. Laparoscopic liver surgery for patients with hepatocellular carcinoma. Ann Surg Oncol 2008;15:800-806 https://doi.org/10.1245/s10434-007-9749-1
- Kaneko H, Takagi S, Otsuka Y, Tsuchiya M, Tamura A, Katagiri T, et al. Laparoscopic liver resection of hepatocellular carcinoma. Am J Surg 2005;189:190-194 https://doi.org/10.1016/j.amjsurg.2004.09.010
- O'Rourke N, Fielding G. Laparoscopic right hepatectomy: surgical technique. J Gastrointest Surg 2004;8:213-216 https://doi.org/10.1016/j.gassur.2003.11.008
- Vibert E, Perniceni T, Levard H, Denet C, Shahri NK, Gayet B. Laparoscopic liver resection. Br J Surg 2006;93: 67-72 https://doi.org/10.1002/bjs.5150
- Ferrero A, Vigano L, Polastri R. Ribero D, Lo Tesoriere R, Muratore, A, et al. Hepatectomy as treatment of choice for hepatocellular carcinoma in elderly cirrhotic patients. World J Surg 2005;29:1101-1105 https://doi.org/10.1007/s00268-005-7768-2
- Ng KK, Vanthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J, et al. Is hepatic resection for large or multinodular hepatocelluar carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 2005;12:364-373 https://doi.org/10.1245/ASO.2005.06.004
- Shah SA, Wei AC, Cleary SP, Yang I, McGilvray ID, Gallinger S, et al. Prognosis and results after resection of very large(>=10cm) hepatocelluar carcinoma. J Gastrointest Surg 2007;11:589-595 https://doi.org/10.1007/s11605-007-0154-7
- Hai L, Yong-Hong P, Yong F, Ren-Feng L. One-stage liver resection for spontaneous rupture of hepatocellular carcinoma. World J Surg 2005;29:1316-1318 https://doi.org/10.1007/s00268-005-7626-2
- Bae JH, Hong SW, Heo TG, Lee H. Characteristics and prognosis after resection for ruptured hepatocellular carcinoma. Korean J Hepatobiliary Pancreat Surg 2006; 10:37-41
- Buczkowski AK, Kim PT, Ho SG, Schaeffer DF, Lee SI, Owen DA, et al. Multidisciplinary management of ruptured hepatocellular carcinoma. J Gastrointest Surg 2006;10:379-386 https://doi.org/10.1016/j.gassur.2005.10.012
- Pawlik TM, Poon RT, Abdalla EK, Ikai I, Nagorney DM, Belghiti J, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005;137:403-410 https://doi.org/10.1016/j.surg.2004.12.012
- Minagawa M, Makuuchi M, Takayama T, Kokudo N. Selection criteria for repeat hepatectomy in patients with recurrent hepatocellular carcinoma. Ann Surg 2003;238: 703-710 https://doi.org/10.1097/01.sla.0000094549.11754.e6
- Kumada T, Nakano S, Takeda I, Sugiyama K, Osada T, Kiriyama S, et al. Patterns of recurrence after initial treatment in patients with small hepatocellular carcinoma. Hepatology 1997;25:87-92 https://doi.org/10.1002/hep.510250116
- Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 1999;229:216-222 https://doi.org/10.1097/00000658-199902000-00009
- Shimada M, Takenaka K, Gion T, Fujiwara Y, Kajiyama K, Maeda T, et al. Prognosis of recurrent hepatocellular carcinoma: a 10-year surgical experience in Japan. Gastroenterology 1996;111:720-726 https://doi.org/10.1053/gast.1996.v111.pm8780578
- Yoon SK. Recent advances in tumor markers of human hepatocellular carcinoma. Intervirology 2008;51(Suppl 1):34-41 https://doi.org/10.1159/000122596
- Kim do Y, Paik YH, Ahn SH, Youn YJ, Choi JW, Kim JK, et al. PIVKA-II is a useful tumor marker for recurrent hepatocellular carcinoma after surgical resection. Oncology 2007;72(Suppl 1):52-57
- Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery 2007;141:330-339 https://doi.org/10.1016/j.surg.2006.06.028
- Samuel M, Chow PK, Chan Shih-Yen E, Machin D, Soo KC. Neoadjuvant and adjuvant therapy for surgical resection of hepatocellular carcinoma. Cochrane Database Syst Rev 2009:CD001199
- Choi GH, Kim DH, Kang CM, Kim KS, Choi JS, Lee WJ, et al. Prognostic factors and optimal treatment strategy for intrahepatic nodular recurrence after curative resection of hepatocellular carcinoma. Ann Surg Oncol 2008;15:618-629 https://doi.org/10.1245/s10434-007-9671-6
- Majno PE, Sarasin FP, Mentha G, Hadengue A. Primary liver resection and salvage transplantation or primary liver transplantation in patients with single, small hepatocellular carcinoma and preserved liver function: an outcomeoriented decision analysis. Hepatology 2000;31:899-906 https://doi.org/10.1053/he.2000.5763
- Katyal S, Oliver JH 3rd, Peterson MS, Ferris JV, Carr BS, Baron RL. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000;216:698-703
- Kuo SW, Chang YL, Huang PM, Hsu HH, Chen JS, Lee JM, et al. Prognostic factors for pulmonary metastasectomy in hepatocellular carcinoma. Ann Surg Oncol 2007;14: 992-997 https://doi.org/10.1245/s10434-006-9217-3
- Nakagawa T, Kamiyama T, Nakanishi K, Yokoo H, Kamachi H, Matsushita M, et al. Pulmonary resection for metastases from hepatocellular carcinoma: factors influencing prognosis. J Thorac Cardiovasc Surg 2006;131: 1248-1254 https://doi.org/10.1016/j.jtcvs.2006.02.009
- Suh KS, Yi NJ. Liver transplantation for hepatocellular carcinoma. Korean J Hepatol 2006;12:493-506
- Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-699 https://doi.org/10.1056/NEJM199603143341104
- Roayaie S, Frischer JS, Emre SH, Fishbein TM, Sheiner PA, Sung M, et al. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters. Ann Surg 2002;235:533-539 https://doi.org/10.1097/00000658-200204000-00012
- Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48(Suppl 1):S20-S37
- Hwang S, Lee SG, Joh JW, Suh KS, Kim DG. Liver transplantation for adult patients with hepatocellular carcinoma in Korea: comparison between cadaveric donor and living donor liver transplantations. Liver Transpl 2005;11:1265-1272 https://doi.org/10.1002/lt.20549
- KONOS. Annual report. www.konos.go.kr. 2007.
- Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-1403 https://doi.org/10.1053/jhep.2001.24563
- Roberts JP. Tumor surveillance-what can and should be done? Screening for recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2005;11(Suppl 2): S45-S46 https://doi.org/10.1002/lt.20605
- Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, et al. The role of (18)F-FDG-PET imaging for the selection of liver transplantation candidates among hepatocellular carcinoma patients. Liver Transpl 2006;12:1655-1660 https://doi.org/10.1002/lt.20861
- Maddala YK, Stadheim L, Andrews JC, Burgart LJ, Rosen CB, Kremers WK, et al. Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization. Liver Transpl 2004;10:449-455 https://doi.org/10.1002/lt.20099
- Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 2002;8:873-883 https://doi.org/10.1053/jlts.2002.34923
- Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002;50:123-128 https://doi.org/10.1136/gut.50.1.123
- Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003;9:557-563 https://doi.org/10.1053/jlts.2003.50106
- Yao FY, Kerlan RK Jr, Hirose R, Davern TJ 3rd, Bass NM, Feng S, et al. Excellent outcome following downstaging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008;48:819-827 https://doi.org/10.1002/hep.22412
- De Luna W, Sze DY, Ahmed A, Ha BY, Ayoub W, Keeffe EB, et al. Transarterial chemoinfusion for hepatocellular carcinoma as downstaging therapy and a bridge toward liver transplantation. Am J Transplant 2009;9:1158-1168 https://doi.org/10.1111/j.1600-6143.2009.02576.x
- Chapman WC, Majella Doyle MB, Stuart JE, Vachharajani N, Crippin JS, Anderson CD, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008;248:617-625
- Yao FY, Hirose R, LaBerge JM, Davern TJ 3rd, Bass NM, Kerlan RK Jr, et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 2005;11:1505-1514 https://doi.org/10.1002/lt.20526
- Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, et al. Radiofrequencyablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004;240:900-909 https://doi.org/10.1097/01.sla.0000143301.56154.95
- Cha CH, Ruo L, Fong Y, Jarnagin WR, Shia J, Blumgart LH, et al. Resection of hepatocellular carcinoma in patients otherwise eligible for transplantation. Ann Surg 2003;238:315-321
- Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002;235:373-382 https://doi.org/10.1097/00000658-200203000-00009
- Belghiti J, Cortes A, Abdalla EK, Regimbeau JM, Prakash K, Durand F, et al. Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 2003;238:885-892 https://doi.org/10.1097/01.sla.0000098621.74851.65
- Hwang S, Lee SG, Moon DB, Ahn CS, Kim KH, Lee YJ, et al. Salvage living donor liver transplantation after prior liver resection for hepatocellular carcinoma. Liver Transpl 2007;13:741-746 https://doi.org/10.1002/lt.21157
- Hwang S, Lee SG, Jung DH, Kim KH, Ha TY, Song GW. Simulation of deceased-donor liver graft allocation as UNOS status I or IIa on the current Korean setting for patients with hepatitis B virus-induced fulminant hepatic failure. Korean J Hepatobiliary Pancreat Surg 2009;13:31-36
- Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: a life-expectancy and costeffectiveness perspective. Hepatology 2001;33:1073-1079 https://doi.org/10.1053/jhep.2001.23311
- Woo HY, Jang JW, Choi JY,You CR, Jeong SW, Bae SH, et al. Living donor liver transplantation in hepatocellular carcinoma beyond the Milan criteria. Liver Int 2008;28:1120-1128 https://doi.org/10.1111/j.1478-3231.2008.01785.x
- Suh KS, Cho EH, Lee HW, Shin WY, Yi NJ, Lee KU. Liver transplantation for hepatocellular carcinoma in patients who do not meet the Milan criteria. Dig Dis 2007;25:329-333 https://doi.org/10.1159/000106913
- Kwon CH, Kim DJ, Han YS, Park JB, Choi GS, Kim SJ, et al. HCC in living donor liver transplantation: can we expand the Milan criteria? Dig Dis 2007;25:313-319 https://doi.org/10.1159/000106911
- Todo S, Furukawa H, Tada M; Japanese Liver Transplantation Study Group. Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2007;13(Suppl 2):S48-S54 https://doi.org/10.1002/lt.21334
- Hwang S, Lee SG, Lee YJ, Sung KB, Park KM, Kim KH, et al. Lessons learned from 1,000 living donor liver transplantations in a single center: how to make living donations safe. Liver Transpl 2006;12:920-927 https://doi.org/10.1002/lt.20734
- Ghobrial RM, Freise CE, Trotter JF, Tong L, Ojo AO, Fair JH, et al. Donor morbidity after living donation for liver transplantation. Gastroenterology 2008:135:468-476 https://doi.org/10.1053/j.gastro.2008.04.018
- Yi NJ, Suh KS, Cho JY, Lee HW, Cho EH, Yang SH, et al. Three-quarters of right liver donors experienced postoperative complications. Liver Transpl 2007;13:797-806 https://doi.org/10.1002/lt.21030
- Akabayashi A, Slingsby BT, Fujita M. The first donor death after living-related liver transplantation in Japan. Transplantation 2004;77:634
- Miller C, Florman S, Kim-Schluger L, Lento P, De La Garza J, Wu J, et al. Fulminant and fatal gas gangrene of the stomach in a healthy live liver donor. Liver Transpl 2004;10:1315-1319 https://doi.org/10.1002/lt.20227
- Melloul E, Dondero F, Paugam-Burtz C, Bouadma L, Arnulf B, Belghiti J. Living liver donor death related to complications of myeloma. Liver Transpl 2009;15:326-329 https://doi.org/10.1002/lt.21685
- Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg 2001;233:652-659 https://doi.org/10.1097/00000658-200105000-00009
- Mazzaferro V, Chun YS, Poon RT, Schwartz ME, Yao FY, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 2008;15:1001-1007 https://doi.org/10.1245/s10434-007-9559-5
- Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43 https://doi.org/10.1016/S1470-2045(08)70284-5
- Marsh JW, Casavilla A, Iwatsuki S, Dvorchik I, Subotin M, Balan V, et al. Predicting the risk of tumor recurrence following transplantation for hepatocellular carcinoma. Hepatology 1997;26:1689-1691 https://doi.org/10.1002/hep.510260650
- Schlitt HJ, Neipp M, Weimann A, Oldhafer KJ, Schmoll E, Boeker K, et al. Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol 1999;17:324-331
- Gondolesi GE, Roayaie S, Munoz L, Kim-Schluger L, Schiano T, Fishbein TM, et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 2004;239: 142-149 https://doi.org/10.1097/01.sla.0000109022.32391.eb
- Yang SH, Suh KS, Lee HW, Cho EH, Cho JY, Cho YB, et al. A revised scoring system utilizing serum alphafetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery 2007; 141:598-609 https://doi.org/10.1016/j.surg.2006.11.006
- Cillo U, Vitale A, Bassanello M, Boccagni P, Brolese A, Zanus G, et al. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma. Ann Surg 2004;239:150-159 https://doi.org/10.1097/01.sla.0000109146.72827.76
- Todo S, Furukawa H; Japanese Study Group on Organ Transplantation. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 2004;240:451-459 https://doi.org/10.1097/01.sla.0000137129.98894.42
- Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, TakagiT, et al. Simultaneous measurements of serum alphafetoproteinand protein induced by vitamin K absence fordetecting hepatocellular carcinoma. South Tohoku DistrictStudy Group. Am J Gastroenterol 2000;95:1036-1040
- Sugawara Y, Tamura S, Makuuchi M. Living donor livertransplantation for hepatocellular carcinoma: Tokyo Universityseries. Dig Dis 2007;25:310-312 https://doi.org/10.1159/000106910
- Ito T, Takada Y, Ueda M, Haga H, Maetani Y, Oike F, etal. Expansion of selection criteria for patients withhepatocellular carcinoma in living donor liver transplantation.Liver Transpl 2007;13:1637-1644 https://doi.org/10.1002/lt.21281
- Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, SungKB, et al. Expanded indication criteria of living donorliver transplantation for hepatocellular carcinoma at onelarge-volume center. Liver Transpl 2008;14:935-945 https://doi.org/10.1002/lt.21445
- Compagnon P, Grandadam S, Lorho R, Turlin B, CamusC, Jianrong Y, et al. Liver transplantation for hepatocellularcarcinoma without preoperative tumor biopsy.Transplantation 2008;86:1068-1076 https://doi.org/10.1097/TP.0b013e318187754c
- Volk M, Marrero JA. Liver transplantation for hepatocellularcarcinoma: who benefits and who is harmed?Gastroenterology 2008;134:1612-1614 https://doi.org/10.1053/j.gastro.2008.03.042
- Jonas S, Bechstein WO, Steinmuller T, Herrmann M,Radke C, Berg T, et al. Vascular invasion and histopathologicgrading determine outcome after liver transplantationfor hepatocellular carcinoma in cirrhosis. Hepatology 2001;33:1080-1086 https://doi.org/10.1053/jhep.2001.23561
- Schwartz M. Liver transplantation for hepatocellular carcinoma.Gastroenterology 2004;127(Suppl 1):S268-S276 https://doi.org/10.1053/j.gastro.2004.09.041
- Schwartz M, Roayaie S, Llovet J. How should patientswith hepatocellular carcinoma recurrence after livertransplantation be treated? J Hepatol 2005;43:584-589 https://doi.org/10.1016/j.jhep.2005.07.019
- Zimmerman MA, Trotter JF, Wachs M, Bak T, CampsenJ, Skibba A, et al. Sirolimus-based immunosuppressionfollowing liver transplantation for hepatocellular carcinoma.Liver Transpl 2008;14:633-638 https://doi.org/10.1002/lt.21420
- Toso C, Meeberg GA, Bigam DL, Oberholzer J, ShapiroAM, Gutfreund K, et al. De novo sirolimus-basedimmunosuppression after liver transplantation for hepatocellularcarcinoma: long-term outcomes and side effects.Transplantation 2007;83:1162-1168 https://doi.org/10.1097/01.tp.0000262607.95372.e0
- Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA,Blitz M, Ma MM, et al. Sirolimus-based immunosuppressionfor liver transplantation in the presence ofextended criteria for hepatocellular carcinoma. LiverTranspl 2004;10:1301-1311 https://doi.org/10.1002/lt.20237
- Hwang S, Lee SG, Ahn CS, Kim KH, Moon DB, Ha TY,et al. Prevention of hepatitis B recurrence after livingdonor liver transplantation: primary high-dose hepatitis Bimmunoglobulin monotherapy and rescue antiviral therapy.Liver Transpl 2008;14:770-778 https://doi.org/10.1002/lt.21440
- Faria LC, Gigou M, Roque-Afonso AM, Sebagh M, RocheB, Fallot G, et al. Hepatocellular carcinoma is associatedwith an increased risk of hepatitis B virus recurrenceafterliver transplantation. Gastroenterology 2008;134:1890-1899 https://doi.org/10.1053/j.gastro.2008.02.064
- Yi NJ, Suh KS, Cho JY, Kwon CH, Lee KW, Joh JW, etal. Recurrence of hepatitis B is associated with cumulativecorticosteroid dose and chemotherapy againsthepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2007;13:451-458 https://doi.org/10.1002/lt.21043
- Sala M, Llovet JM, Vilana R, Bianchi L, Sole M, AyusoC, et al. Initial response to percutaneous ablation predictssurvival in patients with hepatocellular carcinoma. Hepatology 2004;40:1352-1360 https://doi.org/10.1002/hep.20465
- Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma.Lancet 2003;362:1907-1917 https://doi.org/10.1016/S0140-6736(03)14964-1
- Livraghi T, Meloni F, Di Stasi M, Rolle E, Solbiati L,Tinelli C, et al. Sustained complete response and complicationsrates after radiofrequency ablation of very earlyhepatocellular carcinoma in cirrhosis: is resection still thetreatment of choice? Hepatology 2008;47:82-89 https://doi.org/10.1002/hep.21933
- Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, SolbiatiL, Gazelle GS. Small hepatocellular carcinoma: treatmentwith radio-frequency ablation versus ethanol injection.Radiology 1999;210:655-661 https://doi.org/10.1148/radiology.210.3.r99fe40655
- Lencioni RA, Allgaier HP, Cioni D, Olschewski M,Deibert P, Crocetti L, et al. Small hepatocellular carcinomain cirrhosis: randomized comparison of radiofrequencythermal ablation versus percutaneous ethanolinjection. Radiology 2003;228:235-240 https://doi.org/10.1148/radiol.2281020718
- Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Radiofrequencyablation improves prognosis compared withethanol injection for hepatocellular carcinoma < or =4 cm. Gastroenterology 2004;127:1714-1723 https://doi.org/10.1053/j.gastro.2004.09.003
- Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC. Randomisedcontrolled trial comparing percutaneous radiofrequencythermal ablation, percutaneous ethanol injection, andpercutaneous acetic acid injection to treat hepatocellularcarcinoma of 3 cm or less. Gut 2005;54:1151-1156 https://doi.org/10.1136/gut.2004.045203
- Shiina S, Teratani T, Obi S, Sato S, Tateishi R,Fujishima T, et al. A randomized controlled trial ofradiofrequency ablation with ethanol injection for smallhepatocellular carcinoma. Gastroenterology 2005;129:122-130 https://doi.org/10.1053/j.gastro.2005.04.009
- Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G,Moretto P, et al. Radiofrequency ablation versus ethanolinjection for early hepatocellular carcinoma: a randomizedcontrolled trial. Scand J Gastroenterol 2008;43:727-735 https://doi.org/10.1080/00365520701885481
- Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y,et al. Percutaneous radiofrequency ablation for hepatocellularcarcinoma. An analysis of 1000 cases. Cancer 2005;103:1201-1209 https://doi.org/10.1002/cncr.20892
- Choi D, Lim HK, Rhim H, Kim YS, Lee WJ, Paik SW, etal. Percutaneous radiofrequency ablation for early-stagehepatocellular carcinoma as a first-line treatment: longtermresults and prognostic factors in a large singleinstitutionseries. Eur Radiol 2007;17:684-692 https://doi.org/10.1007/s00330-006-0461-5
- Rhim H, Yoon KH, Lee JM, Cho Y, Cho JS, Kim SH, etal. Major complications after radio-frequency thermalablation of hepatic tumors: spectrum of imaging findings.Radiographics 2003;23:123-134 https://doi.org/10.1148/rg.231025054
- de Baere T, Risse O, Kuoch V, Dromain C, Sengel C,Smayra T, et al. Adverse events during radiofrequencytreatment of 582 hepatic tumors. AJR Am J Roentgenol 2003;181:695-700 https://doi.org/10.2214/ajr.181.3.1810695
- Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematicreview of randomized trials for hepatocellular carcinomatreated with percutaneous ablation therapies. Hepatology 2009;49:453-459 https://doi.org/10.1002/hep.22648
- Chen MS, Li JQ, Zheng Y, Guo RP, Liang HH, ZhangYQ, et al. A prospective randomized trial comparingpercutaneous local ablative therapy and partial hepatectomyfor small hepatocellular carcinoma. Ann Surg 2006;243:321-328 https://doi.org/10.1097/01.sla.0000201480.65519.b8
- Hong SN, Lee SY, Choi MS, Lee JH, Koh KC, Paik SW,et al. Comparing the outcomes of radiofrequency ablationand surgery in patients with a single small hepatocellularcarcinoma and well-preserved hepatic function. J Clin Gastroenterol 2005;39:247-252 https://doi.org/10.1097/01.mcg.0000152746.72149.31
- Lupo L, Panzera P, Giannelli G, Memeo M, Gentile A,Memeo V. Single hepatocellular carcinoma ranging from3 to 5 cm: radiofrequency ablation or resection? HPB(Oxford) 2007;9:429-434 https://doi.org/10.1080/13651820701713758
- Abu-Hilal M, Primrose JN, Casaril A, McPhail MJ,Pearce NW, Nicoli N. Surgical resection versus radiofrequencyablation in the treatment of small unifocalhepatocellular carcinoma. J Gastrointest Surg 2008;12:1521-1526 https://doi.org/10.1007/s11605-008-0553-4
- Livraghi T, Bolondi L, Lazzaroni S, Marin G, Morabito A,Rapaccini GL, et al. Percutaneous ethanol injection in thetreatment of hepatocellular carcinoma in cirrhosis. Astudy on 207 patients. Cancer 1992;69:925-929 https://doi.org/10.1002/1097-0142(19920215)69:4<925::AID-CNCR2820690415>3.0.CO;2-G
- Vilana R, Bruix J, Bru C, Ayuso C, Sole M, Rodes J.Tumor size determines the efficacy of percutaneousethanol injection for the treatment of small hepatocellularcarcinoma. Hepatology 1992;16:353-357 https://doi.org/10.1002/hep.1840160212
- Okada S. Local ablation therapy for hepatocellular carcinoma. Semin Liver Dis 1999;19:323-328 https://doi.org/10.1055/s-2007-1007121
- Ishii H, Okada S, Nose H, Okusaka T, Yoshimori M,Takayama T, et al. Local recurrence of hepatocellularcarcinoma after percutaneous ethanol injection. Cancer 1996;77:1792-1796 https://doi.org/10.1002/(SICI)1097-0142(19960501)77:9<1792::AID-CNCR6>3.0.CO;2-E
- Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K,Kojiro M, et al. Results of surgical and nonsurgicaltreatment for small-sized hepatocellular carcinomas: aretrospective and nationwide survey in Japan. The LiverCancer Study Group of Japan. Hepatology 2000;32:1224-1229 https://doi.org/10.1053/jhep.2000.20456
- Ebara M, Okabe S, Kita K, Sugiura N, Fukuda H,Yoshikawa M, et al. Percutaneous ethanol injection forsmall hepatocellular carcinoma: therapeutic efficacy basedon 20-year observation. J Hepatol 2005;43:458-464 https://doi.org/10.1016/j.jhep.2005.03.033
- Huang GT, Lee PH, Tsang YM, Lai MY, Yang PM, HuRH, et al. Percutaneous ethanol injection versus surgicalresection for the treatment of small hepatocellularcarcinoma: a prospective study. Ann Surg 2005;242:36-42 https://doi.org/10.1097/01.sla.0000167925.90380.fe
- Gournay J, Tchuenbou J, Richou C, Masliah C, Lerat F,Dupas B, et al. Percutaneous ethanol injection vs.resection in patients with small single hepatocellularcarcinoma: a retrospective case-control study with costanalysis. Aliment Pharmacol Ther 2002;16:1529-1538 https://doi.org/10.1046/j.1365-2036.2002.01307.x
- Daniele B, De Sio I, Izzo F, Capuano G, Andreana A,Mazzanti R, et al. Hepatic resection and percutaneousethanol injection as treatments of small hepatocellularcarcinoma: a Cancer of the Liver Italian Program (CLIP08) retrospective case-control study. J Clin Gastroenterol 2003;36:63-67 https://doi.org/10.1097/00004836-200301000-00017
- Lai EC, Fan ST, Lo CM, Chu KM, Liu CL, Wong J.Hepatic resection for hepatocellular carcinoma. An auditof 343 patients. Ann Surg 1995;221:291-298
- Matsui O, Kadoya M, Yoshikawa J, Gabata T, TakashimaT, Demachi H. Subsegmental transcatheter arterialembolization for small hepatocellular carcinomas: localtherapeutic effect and 5-year survival rate. Cancer Chemother Pharmacol 1994;33(Suppl 1):S84-S88 https://doi.org/10.1007/BF00686674
- Miyayama S, Matsui O, Yamashiro M, Ryu Y, Kaito K,Ozaki K, et al. Ultraselective transcatheter arterialchemoembolization with a 2-f tip microcatheter for smallhepatocellular carcinomas: relationship between localtumor recurrence and visualization of the portal vein withiodized oil. J Vasc Interv Radiol 2007;18:365-376 https://doi.org/10.1016/j.jvir.2006.12.004
- Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T,et al. Prospective cohort study of transarterial chemoembolizationfor unresectable hepatocellular carcinomain 8510 patients. Gastroenterology 2006;131: 461-469 https://doi.org/10.1053/j.gastro.2006.05.021
- Llovet JM, Real MI, Montana X, Planas R, Coll S, AponteJ, et al. Arterial embolisation or chemoembolisationversus symptomatic treatment in patients with unresectablehepatocellular carcinoma: a randomised controlledtrial. Lancet 2002;359:1734-1739 https://doi.org/10.1016/S0140-6736(02)08649-X
- Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT,et al. Randomized controlled trial of transarterial lipiodolchemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-1171 https://doi.org/10.1053/jhep.2002.33156
- Llovet JM, Bruix J. Systematic review of randomizedtrials for unresectable hepatocellular carcinoma: Chemoembolizationimproves survival. Hepatology 2003;37:429-442 https://doi.org/10.1053/jhep.2003.50047
- Camma C, Schepis F, Orlando A, Albanese M, Shahied L, Trevisani F, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224:47-54 https://doi.org/10.1148/radiol.2241011262
- Lee HS, Kim KM, Yoon JH, Lee TR, Suh KS, Lee KU, et al. Therapeutic efficacy of transcatheter arterial chemoembolization as compared with hepatic resection in hepatocellular carcinoma patients with compensated liver function in a hepatitis B virus-endemic area: a prospective cohort study. J Clin Oncol 2002;20:4459-4465 https://doi.org/10.1200/JCO.2002.02.013
- Lee HS, Kim JS, Choi IJ, Chung JW, Park JH, KimCY. The safety and efficacy of transcatheter arterial chemoembolization in the treatment of patients with hepatocellular carcinoma and main portal vein obstruction. A prospective controlled study. Cancer 1997;79:2087-2094 https://doi.org/10.1002/(SICI)1097-0142(19970601)79:11<2087::AID-CNCR5>3.0.CO;2-M
- Georgiades CS, Hong K, D'Angelo M, Geschwind JF. Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2005;16: 1653-1659 https://doi.org/10.1097/01.RVI.0000182185.47500.7A
- Chung JW, Park JH, Han JK, Choi BI, Han MC. Hepatocellular carcinoma and portal vein invasion: results of treatment with transcatheter oily chemoembolization. AJR Am J Roentgenol 1995;165:315-321 https://doi.org/10.2214/ajr.165.2.7618547
- Park JH, Chung JW, Lee SK, Han JK, Lee HS, Kim CY, et al. Chemoembolization of hepatocellular carcinoma: long-term survival and prognostic factors. J Korean Radiol Soc 1996;35:315-323
- Guo WJ, Yu EX, Liu LM, Li J, Chen Z, Lin JH, et al. Comparison between chemoembolization combined with radiotherapy and chemoembolization alone for large hepatocellular carcinoma. World J Gastroenterol 2003;9:1697-1701
- Shim SJ, Seong J, Han KH, Chon CY, Suh CO, Lee JT. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 2005;25:1189-1196 https://doi.org/10.1111/j.1478-3231.2005.01170.x
- You CR, Jang JW, Kang SH, Bae SH, Choi JY, Yoon SK, et al. Efficacy of transarterial chemolipiodolization with or without 3-dimensional conformal radiotherapy for huge HCC with portal vein tumor thrombosis. Korean J Hepatol 2007;13:378-386 https://doi.org/10.3350/kjhep.2007.13.3.378
- Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier HP. Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 2005;11:6104-6109 https://doi.org/10.3748/wjg.v11.i39.6104
- Yamakado K, Nakatsuka A, Takaki H, Yokoi H, Usui M, Sakurai H, et al. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology 2008;247:260-266 https://doi.org/10.1148/radiol.2471070818
- Hsu HC, Chen TY, Chiu KW, Huang EY, Leung SW, Huang YJ, et al. Three-dimensional conformal radiotherapy for the treatment of arteriovenous shunting in patients with hepatocellular carcinoma. Br J Radiol 2007;80:38-42 https://doi.org/10.1259/bjr/52032397
- Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 2006;12:2563-2567 https://doi.org/10.1158/1078-0432.CCR-05-2225
- Poon RT, Tso WK, Pang RW, Ng KK, Woo R, Tai KS, et al. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drugeluting bead. Clin Gastroenterol Hepatol 2007;5:1100-1108 https://doi.org/10.1016/j.cgh.2007.04.021
- Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007;46:474-481 https://doi.org/10.1016/j.jhep.2006.10.020
- Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008;47:71-81 https://doi.org/10.1002/hep.21980
- Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF, et al. Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 2009;49:1185-1193 https://doi.org/10.1002/hep.22747
- Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005;16:205-213 https://doi.org/10.1097/01.RVI.00001142592.89564.F9
- Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006;106:1653-1663 https://doi.org/10.1002/cncr.21811
- Guo WJ, Yu EX. The long-term efficacy of combined chemoembolization and local irradiation in the treatment of patients with large hepatocellular carcinoma. Hepatogastroenterology 2003;50:500-503
- Seong J, Park HC, Han KH, Chon CY. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 2003;55:329-336 https://doi.org/10.1016/S0360-3016(02)03929-9
- Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 2005;15:279- 283 https://doi.org/10.1016/j.semradonc.2005.04.005
- Kim TH, Kim DY, Park JW, Kim SH, Choi JI, Kim HB, et al. Dose-volumetric parameters predicting radiationinduced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:225-231 https://doi.org/10.1016/j.ijrobp.2006.08.015
- Yamada K, Izaki K, Sugimoto K, Mayahara H, Morita Y, Yoden E, et al. Prospective trial of combined transcatheter arterial chemoembolization and three- dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003;57:113-119 https://doi.org/10.1016/S0360-3016(03)00434-6
- Zeng ZC, Fan J, Tang ZY, Zhou J, Qin LX, Wang JH, et al. A comparison of treatment combinations with and without radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys 2005;61:432-443 https://doi.org/10.1016/j.ijrobp.2004.05.025
- Kim DY, Park W, Lim DH, Lee JH, Yoo BC, Paik SW, et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005;103:2419-2426 https://doi.org/10.1002/cncr.21043
- Meng MB, Cui YL, Lu Y, She B, Chen Y, Guan YS, et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 2009;92:184-194 https://doi.org/10.1016/j.radonc.2008.11.002
- Park W, Lim DH, Paik SW, Koh KC, Choi MS, Park CK, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005;61:1143-1150
- Kim TH, Kim DY, Park JW, Kim YI, Kim SH, Park HS, et al. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol 2006;29:568-575 https://doi.org/10.1097/01.coc.0000239147.60196.11
- Seong J, Lee IJ, Shim SJ, Lim do H, Kim TH, Kim JH, et al. A multicenter retrospective cohort study of practice patterns and clinical outcome on radiotherapy for hepatocellular carcinoma in Korea. Liver Int 2009;29:147-152 https://doi.org/10.1111/j.1478-3231.2008.01873.x
- Dawson LA, McGinn CJ, Lawrence TS. Conformal chemoradiation for primary and metastatic liver malignancies. Semin Surg Oncol 2003;21:249-255 https://doi.org/10.1002/ssu.10043
- Cheng SH, Lin YM, Chuang VP, Yang PS, Cheng JC, Huang AT, et al. A pilot study of three-dimensional conformal radiotherapy in unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 1999;14:1025-1033 https://doi.org/10.1046/j.1440-1746.1999.01994.x
- Huang JF, Wang LY, Lin ZY, Chen SC, Hsieh MY, Chuang WL, et al. Incidence and clinical outcome of icteric type hepatocellular carcinoma. J Gastroenterol Hepatol 2002;17:190-195 https://doi.org/10.1046/j.1440-1746.2002.02677.x
- Yoon SM, Kim JH, Choi EK, Ahn SD, Lee SW, Yi BY. Radioresponse of hepatocellular carcinoma: treatment of lymph node metastasis. Cancer Res Treat 2004;36:79-84 https://doi.org/10.4143/crt.2004.36.1.79
- Park YJ, Lim do H, Paik SW, Koh KC, Lee JH, Choi MS, et al. Radiation therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Gastroenterol 2006;41:1099-1106 https://doi.org/10.1007/s00535-006-1895-x
- Yamashita H, Nakagawa K, Shiraishi K, Tago M, Igaki H, Nakamura N, etal. Radiotherapy for lymph node metastases in patients with hepatocellular carcinoma: retrospective study. J Gastroenterol Hepatol 2007;22: 523-527 https://doi.org/10.1111/j.1440-1746.2006.04450.x
- Zeng ZC, Tang ZY, Fan J, Qin LX, Ye SL, Zhou J, et al. Consideration of role of radiotherapy for lymphnode metastases in patients with HCC: retrospective analysis for prognostic factors from 125 patients. Int J Radiat Oncol Biol Phys 2005;63:1067-1076 https://doi.org/10.1016/j.ijrobp.2005.03.058
- Seong J, Koom WS, Park HC. Radiotherapy for painful bone metastases from hepatocellular carcinoma. Liver Int 2005;25:261-265 https://doi.org/10.1111/j.1478-3231.2005.01094.x
- Kaizu T, Karasawa K, Tanaka Y, Matuda T, Kurosaki H, Tanaka S, et al. Radiotherapy for osseous metastases from hepatocellular carcinoma: a retrospective study of 57 patients. Am J Gastroenterol 1998;93:2167-2171 https://doi.org/10.1111/j.1572-0241.1998.00614.x
- Murakami R, Baba Y, Furusawa M, Yokoyama T, Nishimura R, Uozumi H, et al. Short communication: the value of embolization therapy in painful osseous metastases from hepatocellular carcinomas; comparative study with radiation therapy. Br J Radiol 1996;69:1042-1044 https://doi.org/10.1259/0007-1285-69-827-1042
- Taki Y, Yamaoka Y, Takayasu T, Ino K, Shimahara Y, Mori K, et al. Bone metastases of hepatocellular carcinoma after liver resection. J Surg Oncol 1992;50: 12-18 https://doi.org/10.1002/jso.2930500104
- Choi HJ, Cho BC, Sohn JH, Shin SJ, Kim SH, Kim JH, et al. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol 2009;91:307-313 https://doi.org/10.1007/s11060-008-9713-3
- Nakamura N, Igaki H, Yamashita H, Shiraishi K, Tago M, Sasano N, et al. A retrospective study of radiotherapy for spinal bone metastases from hepatocellular carcinoma (HCC). Jpn J Clin Oncol 2007;37:38-43 https://doi.org/10.1093/jjco/hyl128
- Bush DA, Hillebrand DJ, Slater JM, Slater JD. High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology 2004;127(Suppl 1):S189-S193 https://doi.org/10.1053/j.gastro.2004.09.033
- Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T, et al. Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 2005;23:1839-1846 https://doi.org/10.1200/JCO.2005.00.620
- Chiba T, Tokuuye K, Matsuzaki Y, Sugahara S, Chuganji Y, Kagei K, et al. Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res 2005;11:3799-3805 https://doi.org/10.1158/1078-0432.CCR-04-1350
- Network NCC. NCCN Clinical Practice Guidelines in Oncology - v.2.2008. Hepatobiliary Cancers
- Fong Y KN, Lawrence T. Cancer of the liver and biliary tree. In: De Vita VT, Hellman S, Rosenberg S, eds. Cancer: Principles and Practices of Oncology 2001;1: 1162-1204
- Leung TW, Patt YZ, Lau WY, Ho SK, Yu SC, Chan AT, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999;5:1676-1681
- Leung TW, Tang AM, Zee B, Yu SC, Lai PB, Lau WY, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-alpha, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002;94: 421-427 https://doi.org/10.1002/cncr.10236
- Shim JH, Park JW, Nam BH, Lee WJ, Kim CM. Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma. Cancer Chemother Pharmacol 2009;63:459-467 https://doi.org/10.1007/s00280-008-0759-x
- Johnson PJ. Is there a role for systemic therapy in hepatocellular carcinoma, and if so, can we assess response? Educational book, American Society of Clinical Oncology 2002
- Yuen MF, Poon RT, Lai CL, Fan ST, Lo CM, Wong KW, et al. A randomized placebo-controlled study of longacting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002;36:687-691 https://doi.org/10.1053/jhep.2002.35071
- Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, et al. Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology 2000;31:54-58 https://doi.org/10.1002/hep.510310111
- CLIP Group (Cancer of the Liver Italian Programme). Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. Lancet 1998;352:17-20 https://doi.org/10.1016/S0140-6736(98)01259-8
- Grimaldi C, Bleiberg H, Gay F, Messner M, Rougier P, Kok TC, et al. Evaluation of antiandrogen therapy in unresectable hepatocellular carcinoma: results of a European Organization for Research and Treatment of Cancer multicentric double-blind trial. J Clin Oncol 1998;16:411-417 https://doi.org/10.1200/JCO.1998.16.2.411
- Di Maio M, De Maio E, Perrone F, Pignata S, Daniele B. Hepatocellular carcinoma: systemic treatments. J Clin Gastroenterol 2002;35(Suppl 2):S109-S114 https://doi.org/10.1097/00004836-200211002-00007
- Ganne-Carrie N, Trinchet JC. Systemic treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004;16:275-281
- Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebocontrolled trial. Lancet Oncol 2009;10:25-34 https://doi.org/10.1016/S1470-2045(08)70285-7
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-390 https://doi.org/10.1056/NEJMoa0708857
- Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008;99:159-165
- Shim JH, Park JW, Choi JI, Park BJ, Kim CM. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. J Cancer Res Clin Oncol 2009;135: 617-625 https://doi.org/10.1007/s00432-008-0496-x
- Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, et al. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004;15:1661-1666 https://doi.org/10.1093/annonc/mdh430
- Nagamatsu H, Itano S, Nagaoka S, Akiyoshi J, Matsugaki S, Kurogi J, et al. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy. Am J Gastroenterol 2004;99:2369-2375 https://doi.org/10.1111/j.1572-0241.2004.40069.x
- Lalazar G, Rund D, Shouval D. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies. Br J Haematol 2007;136: 699-712 https://doi.org/10.1111/j.1365-2141.2006.06465.x
- Lau GK, He ML, Fong DY, Bartholomeusz A, Au WY, Lie AK, et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002;36:702-709 https://doi.org/10.1053/jhep.2002.35068
- Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006;4:1076-1081 https://doi.org/10.1016/j.cgh.2006.05.027
- Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307 https://doi.org/10.1002/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0
- Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-539
- Park JW, Park KW, Cho SH, Park HS, Lee WJ, Lee DH, et al. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV-related hepatocellular carcinoma: report of a prospective study. Am J Gastroenterol 2005; 100:2194-2200 https://doi.org/10.1111/j.1572-0241.2005.00232.x
- Jang JW, Choi JY, Bae SH, Yoon SK, Chang UI, Kim CW, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemolipiodolization. Hepatology 2006;43:233-240 https://doi.org/10.1002/hep.21024
- Firpi RJ, Nelson DR. Management of viral hepatitis in hematologic malignancies. Blood Rev 2008;22:117-126 https://doi.org/10.1016/j.blre.2008.02.001
- Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008;148:519-528 https://doi.org/10.1001/archinte.148.3.519
- Kubo S, Nishiguchi S, Hamba H, Hirohashi K, Tanaka H, Shuto T, et al. Reactivation of viral replication after liver resection in patients infected with hepatitis B virus. Ann Surg 2001;233:139-145 https://doi.org/10.1097/00000658-200101000-00020
- Kim JH, Park JW, Kim TH, Koh DW, Lee WJ, Kim CM. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in patients with hepatitis B virus-related hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2007;69:813-819 https://doi.org/10.1016/j.ijrobp.2007.04.005
- Jang JW, Choi JY, Bae SH, Kim CW, Yoon SK, Cho SH, et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 2004;41:427-435 https://doi.org/10.1016/j.jhep.2004.05.014
- Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228-232 https://doi.org/10.1053/jhep.2000.9409
- Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543-1554 https://doi.org/10.1002/hep.21415
- Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214 https://doi.org/10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6
- Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response totreatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216 https://doi.org/10.1093/jnci/92.3.205
- Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247 https://doi.org/10.1016/j.ejca.2008.10.026
- Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona- 2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430 https://doi.org/10.1016/S0168-8278(01)00130-1
- Walzer N, Kulik LM. Hepatocellular carcinoma: latest developments. Curr Opin Gastroenterol 2008;24:312-319 https://doi.org/10.1097/MOG.0b013e3282fafef3
- Okada S, Shimada K, Yamamoto J, Takayama T, Kosuge T, Yamasaki S, et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 1994;106:1618-1624 https://doi.org/10.1016/0016-5085(94)90419-7
- Shirabe K, Kanematsu T, Matsumata T, AdachiE, Akazawa K, Sugimachi K. Factors linked to early recurrence of small hepatocellular carcinoma after hepatectomy: univariate and multivariate analyses. Hepatology 1991;14:802-805 https://doi.org/10.1002/hep.1840140510
- Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 2003;38:200-207
- Adachi E, Maeda T, Matsumata T, Shirabe K, Kinukawa N, Sugimachi K, et al. Risk factors for intrahepatic recurrence in human small hepatocellular carcinoma. Gastroenterology 1995;108:768-775 https://doi.org/10.1016/0016-5085(95)90450-6
- Horiike N, Iuchi H, Ninomiya T, Kawai K, Kumagi T, Michitaka K, et al. Influencing factors for recurrence of hepatocellular carcinoma treated with radiofrequency ablation. Oncol Rep 2002;9:1059-1062
- Hori T, Nagata K, Hasuike S, Onaga M, Motoda M, Moriuchi A, et al. Risk factors for the local recurrence of hepatocellular carcinoma after a single session of percutaneous radiofrequency ablation. J Gastroenterol 2003; 38:977-981 https://doi.org/10.1007/s00535-003-1181-0
- Kim YS, Rhim H, Cho OK, Koh BH, Kim Y. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors. Eur J Radiol 2006;59:432-441 https://doi.org/10.1016/j.ejrad.2006.03.007
- Bleicher RJ, Allegra DP, Nora DT, Wood TF, Foshag LJ, Bilchik AJ. Radiofrequency ablation in 447 complex unresectable liver tumors: lessons learned. Ann Surg Oncol 2003;10:52-58 https://doi.org/10.1245/ASO.2003.03.018
- Kuvshinoff BW, Ota DM. Radiofrequency ablation of liver tumors: influence of technique and tumor size. Surgery 2002;132:605-611 https://doi.org/10.1067/msy.2002.127545
- Komorizono Y, Oketani M, Sako K, Yamasaki N, Shibatou T, Maeda M, et al. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer 2003;97:1253-1262 https://doi.org/10.1002/cncr.11168
- Lu DS, Raman SS, Limanond P, Aziz D, Economou J, Busuttil R, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol 2003;14:1267-1274 https://doi.org/10.1097/01.RVI.0000092666.72261.6B
- Lam VW, Ng KK, Chok KS, Cheung TT, Yuen J, Tung H, et al. Risk factors and prognostic factors of local recurrence after radiofrequency ablation of hepatocellular carcinoma. J Am Coll Surg 2008;207:20-29 https://doi.org/10.1016/j.jamcollsurg.2008.01.020
- Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl 2004;10:911-918 https://doi.org/10.1002/lt.20140
- Lohe F, Angele MK, Gerbes AL, Lohrs U, Jauch KW, Schauer RJ. Tumour size is an important predictor for the outcome after liver transplantation for hepatocellular carcinoma. Eur J Surg Oncol 2005;31:994-999 https://doi.org/10.1016/j.ejso.2005.06.003
- Roayaie S, Schwartz JD, Sung MW, Emre SH, Miller CM, Gondolesi GE, et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004;10:534-540 https://doi.org/10.1002/lt.20128
- Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, et al. Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. Arch Surg 2008;143:182-188 https://doi.org/10.1001/archsurg.2007.39
Cited by
- Current status of liver diseases in Korea: Hepatocellular carcinoma vol.15, pp.suppl6, 2009, https://doi.org/10.3350/kjhep.2009.15.s6.s50
- Liver Transplantation for Advanced Hepatocellular Carcinoma vol.24, pp.1, 2010, https://doi.org/10.4285/jkstn.2010.24.1.4
- Eastern asian expert panel opinion: designing clinical trials of molecular targeted therapy for hepatocellular carcinoma vol.10, pp.None, 2009, https://doi.org/10.1186/1471-2407-10-620
- 작은 크기의 재발성 간세포암에 대한 구제치료로 소분할 방사선치료: 국소 제어율과 안전성 vol.28, pp.2, 2009, https://doi.org/10.3857/jkstro.2010.28.2.85
- Liver Cancer Working Group Report vol.40, pp.suppl1, 2009, https://doi.org/10.1093/jjco/hyq123
- Effect of alcohol on the development of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis: a cross-sectional case-control study vol.16, pp.3, 2009, https://doi.org/10.3350/kjhep.2010.16.3.308
- Long-term outcome of preoperative transarterial chemoembolization and hepatic resection in patients with hepatocellular carcinoma vol.16, pp.4, 2009, https://doi.org/10.3350/kjhep.2010.16.4.383
- Superior long-term outcomes after surgery in child-pugh class a patients with single small hepatocellular carcinoma compared to radiofrequency ablation vol.5, pp.2, 2009, https://doi.org/10.1007/s12072-010-9237-8
- Usefulness of Bremsstrahlung Images after Intra-arterial Y-90 Resin Microphere Radioembolization for Hepatic Tumors vol.45, pp.1, 2009, https://doi.org/10.1007/s13139-010-0066-4
- Survival of patients with advanced hepatocellular carcinoma: Sorafenib versus other treatments vol.26, pp.11, 2009, https://doi.org/10.1111/j.1440-1746.2011.06751.x
- Prognostic Index for Portal Vein Tumor Thrombosis in Patients with Hepatocellular Carcinoma Treated with Radiation Therapy vol.26, pp.8, 2009, https://doi.org/10.3346/jkms.2011.26.8.1014
- The retrospective cohort study for survival rate in patients with advanced hepatocellular carcinoma receiving radiotherapy or palliative care vol.17, pp.3, 2009, https://doi.org/10.3350/kjhep.2011.17.3.189
- Radiation Therapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis vol.29, pp.1, 2011, https://doi.org/10.3857/jkstro.2011.29.1.36
- Super-selection of a Subgroup of Hepatocellular Carcinoma Patients at Minimal Risk of Recurrence for Liver Transplantation vol.15, pp.6, 2011, https://doi.org/10.1007/s11605-011-1467-0
- Molecularly Targeted Therapies for Hepatocellular Carcinoma: Sorafenib as a Stepping Stone vol.29, pp.3, 2009, https://doi.org/10.1159/000327563
- Asian Consensus Workshop Report: Expert Consensus Guideline for the Management of Intermediate and Advanced Hepatocellular Carcinoma in Asia vol.81, pp.suppl1, 2011, https://doi.org/10.1159/000333280
- Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma vol.27, pp.6, 2012, https://doi.org/10.1111/j.1440-1746.2011.06963.x
- The management of hepatocellular carcinoma around the world: a comparison of guidelines from 2001 to 2011 vol.32, pp.7, 2009, https://doi.org/10.1111/j.1478-3231.2012.02792.x
- Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long‐term clinical outcomes of 1717 treatment‐naïve p vol.32, pp.7, 2009, https://doi.org/10.1111/j.1478-3231.2012.02811.x
- Scheduled Interval Trans-Catheter Arterial Chemoembolization Followed by Radiation Therapy in Patients with Unresectable Hepatocellular Carcinoma vol.27, pp.7, 2012, https://doi.org/10.3346/jkms.2012.27.7.736
- KASL Clinical Practice Guidelines: Management of chronic hepatitis B vol.18, pp.2, 2012, https://doi.org/10.3350/cmh.2012.18.2.109
- Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period vol.18, pp.3, 2009, https://doi.org/10.3350/cmh.2012.18.3.258
- Type and cause of liver disease in Korea: single-center experience, 2005-2010 vol.18, pp.3, 2009, https://doi.org/10.3350/cmh.2012.18.3.309
- Risk Factors of Cryptogenic Hepatocellular Carcinoma in Patients with Low Body Mass Index or without Metabolic Syndrome vol.27, pp.1, 2009, https://doi.org/10.3904/kjim.2012.27.1.47
- The Optimal Selection of Radiotherapy Treatment for Hepatocellular Carcinoma vol.6, pp.2, 2009, https://doi.org/10.5009/gnl.2012.6.2.139
- The Clinical and Laboratory Characteristics of Patients with Chronic Hepatitis B Using Current or Past Antiviral Therapy in Korea: A Multi-Center, Nation-Wide, Cross-Sectional Epidemiologic Study vol.6, pp.2, 2009, https://doi.org/10.5009/gnl.2012.6.2.241
- Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma vol.56, pp.6, 2012, https://doi.org/10.1016/j.jhep.2012.01.006
- Changes of the liver volume and the Child-Pugh score after high dose hypofractionated radiotherapy in patients with small hepatocellular carcinoma vol.30, pp.4, 2009, https://doi.org/10.3857/roj.2012.30.4.189
- Two‐week schedule of hypofractionated radiotherapy as a local salvage treatment for small hepatocellular carcinoma vol.28, pp.10, 2009, https://doi.org/10.1111/jgh.12249
- Worse outcome of sorafenib therapy associated with ascites and Child‐Pugh score in advanced hepatocellular carcinoma vol.28, pp.11, 2009, https://doi.org/10.1111/jgh.12310
- Early on‐treatment change in liver stiffness predicts development of liver‐related events in chronic hepatitis B patients receiving antiviral therapy vol.33, pp.2, 2009, https://doi.org/10.1111/liv.12020
- Risk factors and a predictive model for acute hepatic failure after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma vol.33, pp.2, 2009, https://doi.org/10.1111/liv.12023
- Clinical features and outcome of cryptogenic hepatocellular carcinoma compared to those of viral and alcoholic hepatocellular carcinoma vol.13, pp.None, 2009, https://doi.org/10.1186/1471-2407-13-335
- Prognostic value of C-reactive protein and neutrophil-to-lymphocyte ratio in patients with hepatocellular carcinoma vol.13, pp.None, 2013, https://doi.org/10.1186/1471-2407-13-78
- Status of Primary Liver Cancer Found through Routine Health Check-up vol.28, pp.10, 2013, https://doi.org/10.3346/jkms.2013.28.10.1449
- Feasibility and Efficacy of Stereotactic Ablative Radiotherapy for Barcelona Clinic Liver Cancer-C Stage Hepatocellular Carcinoma vol.28, pp.2, 2013, https://doi.org/10.3346/jkms.2013.28.2.213
- Feasibility of Sorafenib Combined with Local Radiotherapy in Advanced Hepatocellular Carcinoma vol.54, pp.5, 2009, https://doi.org/10.3349/ymj.2013.54.5.1178
- Current consensus and guidelines of contrast enhanced ultrasound for the characterization of focal liver lesions vol.19, pp.1, 2009, https://doi.org/10.3350/cmh.2013.19.1.1
- Factors influencing hepatocellular carcinoma prognosis after hepatectomy: a single-center experience vol.28, pp.4, 2009, https://doi.org/10.3904/kjim.2013.28.4.428
- Treatment Outcomes of Helical Intensity-Modulated Radiotherapy for Unresectable Hepatocellular Carcinoma vol.7, pp.3, 2009, https://doi.org/10.5009/gnl.2013.7.3.343
- Is It Time to Adopt External Beam Radiotherapy in the NCCN Guidelines as a Therapeutic Strategy for Intermediate/Advanced Hepatocellular Carcinoma? vol.84, pp.suppl1, 2013, https://doi.org/10.1159/000345893
- Number of Target Lesions for EASL and Modified RECIST to Predict Survivals in Hepatocellular Carcinoma Treated with Chemoembolization vol.19, pp.6, 2013, https://doi.org/10.1158/1078-0432.ccr-12-2721
- National Cancer Screening Program for Hepatocellular Carcinoma vol.84, pp.5, 2013, https://doi.org/10.3904/kjm.2013.84.5.670
- The Korean National Liver Cancer Surveillance Program: Experience of a Single Healthcare Center in 2011 vol.84, pp.5, 2009, https://doi.org/10.3904/kjm.2013.84.5.672
- Efficacy of Sorafenib Monotherapy versus Sorafenib-Based Loco-Regional Treatments in Advanced Hepatocellular Carcinoma vol.8, pp.10, 2009, https://doi.org/10.1371/journal.pone.0077240
- Recent advances in hepatic resection and liver transplantation for hepatocellular carcinoma vol.56, pp.11, 2009, https://doi.org/10.5124/jkma.2013.56.11.956
- Recent advance of local ablation for hepatocellular carcinoma vol.56, pp.11, 2009, https://doi.org/10.5124/jkma.2013.56.11.964
- Recent developments in radiotherapy for hepatocellular carcinoma vol.56, pp.11, 2009, https://doi.org/10.5124/jkma.2013.56.11.983
- Recent advances in systemic chemotherapy of hepatocellular carcinoma vol.56, pp.11, 2009, https://doi.org/10.5124/jkma.2013.56.11.993
- The Use of Proton Therapy in the Treatment of Gastrointestinal Cancers : Liver vol.20, pp.6, 2009, https://doi.org/10.1097/ppo.0000000000000082
- Clinical outcomes of a cohort series of patients with hepatocellular carcinoma in a hepatitis B virus‐endemic area vol.29, pp.4, 2009, https://doi.org/10.1111/jgh.12470
- Long‐term outcomes of chronic hepatitis B virus infection in the era of antiviral therapy in Korea vol.29, pp.5, 2009, https://doi.org/10.1111/jgh.12478
- Long‐term survival after surgical resection for huge hepatocellular carcinoma: Comparison with transarterial chemoembolization after propensity score matching vol.29, pp.5, 2009, https://doi.org/10.1111/jgh.12504
- Role of lamivudine with transarterial chemoembolization in the survival of patients with hepatocellular carcinoma vol.29, pp.6, 2009, https://doi.org/10.1111/jgh.12554
- Therapeutic benefit of radiotherapy in huge (≥10?cm) unresectable hepatocellular carcinoma vol.34, pp.5, 2009, https://doi.org/10.1111/liv.12436
- The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma vol.34, pp.5, 2014, https://doi.org/10.1111/liv.12445
- Conventional fractionated helical tomotherapy for patients with small to medium hepatocellular carcinomas without portal vein tumor thrombosis vol.7, pp.None, 2014, https://doi.org/10.2147/ott.s69618
- Added Value of Diffusion-Weighted MRI for Evaluating Viable Tumor of Hepatocellular Carcinomas Treated With Radiotherapy in Patients With Chronic Liver Disease vol.202, pp.1, 2009, https://doi.org/10.2214/ajr.12.10212
- Hepatic Arterial Phase on Gadoxetic Acid-Enhanced Liver MR Imaging: A Randomized Comparison of 0.5 mL/s and 1 mL/s Injection Rates vol.15, pp.5, 2014, https://doi.org/10.3348/kjr.2014.15.5.605
- Role of Radiofrequency Ablation in Patients with Hepatocellular Carcinoma Who Undergo Prior Transarterial Chemoembolization: Long-Term Outcomes and Predictive Factors vol.8, pp.5, 2014, https://doi.org/10.5009/gnl13356
- Effective Biliary Drainage and Proper Treatment Improve Outcomes of Hepatocellular Carcinoma with Obstructive Jaundice vol.8, pp.5, 2009, https://doi.org/10.5009/gnl13370
-
Transcatheter arterial chemoembolization and radiation therapy for treatment-na
$\ddot{i}$ ve patients with locally advanced hepatocellular carcinoma vol.32, pp.1, 2009, https://doi.org/10.3857/roj.2014.32.1.14 - Clinical Features of Non-alcoholic Fatty Liver Disease in Cryptogenic Hepatocellular Carcinoma vol.63, pp.5, 2014, https://doi.org/10.4166/kjg.2014.63.5.292
- Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first‐line therapy: A Korean multicenter study vol.29, pp.7, 2009, https://doi.org/10.1111/jgh.12542
- A comparison between surgical resection and radiofrequency ablation in the treatment of hepatocellular carcinoma vol.87, pp.2, 2009, https://doi.org/10.4174/astr.2014.87.2.72
- Effectiveness and safety of proton beam therapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis vol.190, pp.9, 2014, https://doi.org/10.1007/s00066-014-0604-6
- Oral antiviral therapy improves the diagnostic accuracy of alpha‐fetoprotein levels in patients with chronic hepatitis B vol.29, pp.9, 2014, https://doi.org/10.1111/jgh.12612
- Long‐term outcomes of second treatment after initial transarterial chemoembolization in patients with hepatocellular carcinoma vol.34, pp.8, 2009, https://doi.org/10.1111/liv.12535
- Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma vol.190, pp.10, 2009, https://doi.org/10.1007/s00066-014-0643-z
- Comparison of Clinical Manifestations and Outcomes between Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma: Analysis of a Nationwide Cohort vol.9, pp.11, 2014, https://doi.org/10.1371/journal.pone.0112184
- Comparison of Malnutrition Risk between Patients with Liver Cirrhosis and Viral Hepatitis Carrier: A Single Center Study vol.64, pp.5, 2014, https://doi.org/10.4166/kjg.2014.64.5.284
- Outcomes after curative hepatectomy in patients with non‐B non‐C hepatocellular carcinoma and hepatitis B virus hepatocellular carcinoma from non‐cirrhotic liver vol.110, pp.8, 2009, https://doi.org/10.1002/jso.23772
- Image-guided Treatment in the Hepatobiliary System: Role of Imaging in Treatment Planning and Posttreatment Evaluation vol.35, pp.5, 2009, https://doi.org/10.1148/rg.2015140281
- Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma vol.2015, pp.None, 2015, https://doi.org/10.1155/2015/181065
- Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib vol.2, pp.None, 2009, https://doi.org/10.2147/jhc.s79353
- Hepatocellular Carcinoma Risk of Compensated Cirrhosis Patients with Elevated HBV DNA Levels according to Serum Aminotransferase Levels vol.30, pp.11, 2009, https://doi.org/10.3346/jkms.2015.30.11.1618
- Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy vol.21, pp.3, 2009, https://doi.org/10.3350/cmh.2015.21.3.287
- 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma vol.9, pp.3, 2009, https://doi.org/10.5009/gnl14460
- Reappraisal of serum alpha‐foetoprotein as a surveillance test for hepatocellular carcinoma during entecavir treatment vol.35, pp.1, 2015, https://doi.org/10.1111/liv.12516
- Incidental Microscopic Bile Duct Tumor Thrombi in Hepatocellular Carcinoma after Curative Hepatectomy : A Matched Study vol.94, pp.6, 2009, https://doi.org/10.1097/md.0000000000000450
- Prevalence, Risk Factors and Clinical Characteristics in Patients with Genotype 6 Chronic Hepatitis C: A Single Institute Experience vol.65, pp.2, 2009, https://doi.org/10.4166/kjg.2015.65.2.105
- Optimal follow-up duration for evaluating objective response to radiotherapy in patients with hepatocellular carcinoma: a retrospective study vol.34, pp.2, 2015, https://doi.org/10.5732/cjc.014.10136
- Liver stiffness‐based model for prediction of hepatocellular carcinoma in chronic hepatitis B virus infection: comparison with histological fibrosis vol.35, pp.3, 2015, https://doi.org/10.1111/liv.12621
- The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: Final results of the START trial vol.136, pp.6, 2009, https://doi.org/10.1002/ijc.29126
- A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis vol.50, pp.4, 2009, https://doi.org/10.1007/s00535-014-0978-3
- Different Survival of Barcelona Clinic Liver Cancer Stage C Hepatocellular Carcinoma Patients by the Extent of Portal Vein Invasion and the Type of Extrahepatic Spread vol.10, pp.4, 2009, https://doi.org/10.1371/journal.pone.0124434
- Current management of hepatocellular carcinoma: An Eastern perspective vol.21, pp.13, 2015, https://doi.org/10.3748/wjg.v21.i13.3826
- 2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma vol.16, pp.3, 2015, https://doi.org/10.3348/kjr.2015.16.3.465
- The Korean guideline for hepatocellular carcinoma surveillance vol.58, pp.5, 2015, https://doi.org/10.5124/jkma.2015.58.5.385
- Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib vol.30, pp.6, 2009, https://doi.org/10.1111/jgh.12898
- Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study vol.35, pp.9, 2009, https://doi.org/10.1111/liv.12818
- Korean Version of a Model to Estimate Survival in Ambulatory Patients with Hepatocellular Carcinoma (K-MESIAH) vol.10, pp.10, 2015, https://doi.org/10.1371/journal.pone.0138374
- Prognostic indicators for radiotherapy of abdominal lymph node metastases from hepatocellular carcinoma vol.191, pp.11, 2009, https://doi.org/10.1007/s00066-015-0873-8
- The prognosis in cases of hepatocellular carcinoma after hepatectomy: young patients versus older patients vol.19, pp.4, 2009, https://doi.org/10.14701/kjhbps.2015.19.4.154
- Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions vol.15, pp.None, 2009, https://doi.org/10.1186/s12885-015-1273-2
- Normal liver sparing by proton beam therapy for hepatocellular carcinoma: Comparison with helical intensity modulated radiotherapy and volumetric modulated arc therapy vol.54, pp.10, 2009, https://doi.org/10.3109/0284186x.2015.1009637
- Rate of observation and inter-observer agreement for LI-RADS major features at CT and MRI in 184 pathology proven hepatocellular carcinomas vol.41, pp.5, 2009, https://doi.org/10.1007/s00261-015-0623-5
- Anatomical Resection But Not Surgical Margin Width Influence Survival Following Resection for HCC, A Propensity Score Analysis vol.40, pp.6, 2009, https://doi.org/10.1007/s00268-016-3421-5
- Radiotherapy in the multidisciplinary treatment of liver cancer: a survey on behalf of the Italian Association of Radiation Oncology vol.121, pp.9, 2009, https://doi.org/10.1007/s11547-016-0650-5
- Factors determining long-term outcomes of hepatocellular carcinoma within the Milan criteria: liver transplantation versus locoregional therapy : A retrospective cohort study vol.95, pp.35, 2016, https://doi.org/10.1097/md.0000000000004735
- The utility of gadoxetic acid-enhanced magnetic resonance imaging in the surveillance for postoperative recurrence of hepatocellular carcinoma vol.95, pp.51, 2009, https://doi.org/10.1097/md.0000000000005666
- The effect of radiotherapy in liver-confined but non-resectable Barcelona Clinic Liver Cancer stage C large hepatocellular carcinoma vol.7, pp.38, 2009, https://doi.org/10.18632/oncotarget.10908
- Transarterial chemoembolization versus resection for intermediate-stage (BCLC B) hepatocellular carcinoma vol.22, pp.2, 2016, https://doi.org/10.3350/cmh.2016.0015
- Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma vol.22, pp.4, 2016, https://doi.org/10.3350/cmh.2016.0048
- KASL clinical practice guidelines: management of chronic hepatitis B vol.22, pp.1, 2009, https://doi.org/10.3350/cmh.2016.22.1.18
- Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma vol.22, pp.1, 2009, https://doi.org/10.3748/wjg.v22.i1.262
- Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index vol.10, pp.5, 2009, https://doi.org/10.5009/gnl15368
- Lamivudine versus Entecavir for Newly Diagnosed Hepatitis B Virus-Related Hepatocellular Carcinoma vol.10, pp.6, 2009, https://doi.org/10.5009/gnl15527
- The meaning of gross tumor type in the aspects of cytokeratin 19 expression and resection margin in patients with hepatocellular carcinoma vol.31, pp.1, 2009, https://doi.org/10.1111/jgh.13063
- Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial‐embolization prognostic score vol.36, pp.1, 2009, https://doi.org/10.1111/liv.12878
- Hepatic Venous Pressure Gradient Predicts Long-Term Mortality in Patients with Decompensated Cirrhosis vol.57, pp.1, 2009, https://doi.org/10.3349/ymj.2016.57.1.138
- The management and prognosis of patients with hepatocellular carcinoma: what has changed in 20 years? vol.36, pp.3, 2009, https://doi.org/10.1111/liv.12960
- Use of Wisteria Floribunda Agglutinin-Positive Human Mac-2 Binding Protein in Assessing Risk of Hepatocellular Carcinoma Due to Hepatitis B Virus vol.95, pp.14, 2009, https://doi.org/10.1097/md.0000000000003328
- Higher Ratio of Serum Alpha-Fetoprotein Could Predict Outcomes in Patients with Hepatitis B Virus-Associated Hepatocellular Carcinoma and Normal Alanine Aminotransferase vol.11, pp.6, 2009, https://doi.org/10.1371/journal.pone.0157299
- 간이식 환자의 뇌경색에 대한 한의학적 치료 증례보고 vol.24, pp.3, 2009, https://doi.org/10.14374/hfs.2016.24.3.225
- Impact of the activity calculation method used in transarterial radioembolization: a dosimetric comparison between 90Y-SIRSphere and 90Y-TheraSphere therapy vol.37, pp.9, 2016, https://doi.org/10.1097/mnm.0000000000000544
- The recommended treatment algorithms of the BCLC and HKLC staging systems: does following these always improve survival rates for HCC patients? vol.36, pp.10, 2016, https://doi.org/10.1111/liv.13107
- Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis vol.62, pp.3, 2009, https://doi.org/10.1007/s10620-016-4431-8
- Peritumoral decreased uptake area of gadoxetic acid enhanced magnetic resonance imaging and tumor recurrence after surgical resection in hepatocellular carcinoma : A STROBE-compliant article vol.96, pp.33, 2017, https://doi.org/10.1097/md.0000000000007761
- The role of scheduled second TACE in early-stage hepatocellular carcinoma with complete response to initial TACE vol.23, pp.1, 2009, https://doi.org/10.3350/cmh.2016.0058
- Clinical Practice Patterns of Radiotherapy in Patients with Hepatocellular Carcinoma: A Korean Radiation Oncology Group Study (KROG 14-07) vol.49, pp.1, 2009, https://doi.org/10.4143/crt.2016.097
- Sorafenib combined with hepatectomy in patients with intermediate-stage and advanced hepatocellular carcinoma vol.13, pp.6, 2017, https://doi.org/10.5114/aoms.2017.71066
- Strategies to tackle the challenges of external beam radiotherapy for liver tumors vol.9, pp.14, 2009, https://doi.org/10.4254/wjh.v9.i14.645
- Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma vol.96, pp.11, 2009, https://doi.org/10.1097/md.0000000000005811
- A model predicting survival of patients with recurrent or progressive hepatocellular carcinoma: the MORE score vol.32, pp.3, 2009, https://doi.org/10.1111/jgh.13532
- Prognostic significance of microvascular invasion in tumor stage for hepatocellular carcinoma vol.15, pp.None, 2009, https://doi.org/10.1186/s12957-017-1292-3
- Novel Albumin-Bilirubin Grade-Based Risk Prediction Model for Patients with Hepatocellular Carcinoma Undergoing Chemoembolization vol.63, pp.4, 2009, https://doi.org/10.1007/s10620-018-4934-6
- Predictive Value of Procalcitonin for Bacterial Infection after Transarterial Chemoembolization or Radiofrequency Ablation for Hepatocellular Carcinoma vol.2018, pp.None, 2018, https://doi.org/10.1155/2018/9120878
- Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment? vol.53, pp.6, 2009, https://doi.org/10.1080/00365521.2018.1458895
- Transarterial chemoembolization extends long-term survival in patients with unresectable hepatocellular carcinoma vol.97, pp.33, 2009, https://doi.org/10.1097/md.0000000000011872
- Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib vol.38, pp.9, 2009, https://doi.org/10.1111/liv.13731
- Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma vol.24, pp.35, 2009, https://doi.org/10.3748/wjg.v24.i35.4000
- Survival benefit of higher fraction dose delivered by three-dimensional conformal radiotherapy in hepatocellular carcinoma smaller than 10 cm in size vol.11, pp.None, 2009, https://doi.org/10.2147/cmar.s179540
- Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma? vol.11, pp.2, 2019, https://doi.org/10.3390/cancers11020230
- Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B vol.25, pp.1, 2009, https://doi.org/10.3350/cmh.2018.0040
- Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment? vol.14, pp.3, 2009, https://doi.org/10.1371/journal.pone.0213547
- Liver resection versus transarterial chemoembolization for the treatment of intermediate‐stage hepatocellular carcinoma vol.8, pp.4, 2009, https://doi.org/10.1002/cam4.2038
- Refractoriness to transarterial chemoembolization in patients with recurrent hepatocellular carcinoma after curative resection vol.14, pp.4, 2009, https://doi.org/10.1371/journal.pone.0214613
- Stem Cell Markers Predict the Response to Sorafenib in Patients with Hepatocellular Carcinoma vol.13, pp.3, 2019, https://doi.org/10.5009/gnl18345
- 2018 Korean Liver Cancer Association–National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma vol.13, pp.3, 2009, https://doi.org/10.5009/gnl19024
- Design and validation of risk prediction model for hepatocellular carcinoma development after sustained virological response in patients with chronic hepatitis C vol.32, pp.3, 2009, https://doi.org/10.1097/meg.0000000000001512
- Potential etiology, prevalence of cirrhosis, and mode of detection among patients with non-B non-C hepatocellular carcinoma in Korea vol.35, pp.1, 2009, https://doi.org/10.3904/kjim.2018.040
- Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma vol.14, pp.2, 2009, https://doi.org/10.1007/s12072-020-10014-4
- Statin Use and the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B vol.71, pp.6, 2020, https://doi.org/10.1002/hep.30973
- Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma vol.12, pp.6, 2009, https://doi.org/10.4251/wjgo.v12.i6.663
- Comparison of LI-RADS 2018 and KLCA-NCC 2018 for noninvasive diagnosis of hepatocellular carcinoma using magnetic resonance imaging vol.26, pp.3, 2020, https://doi.org/10.3350/cmh.2020.0004
- Proposal of a New Risk Score for Patients Treated with Transarterial Chemoembolization due to Recurrent Hepatocellular Carcinoma after Curative Resection: A Multicenter Study vol.14, pp.4, 2020, https://doi.org/10.5009/gnl19111
- Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial vol.74, pp.3, 2021, https://doi.org/10.1016/j.jhep.2020.09.026
- Prognosis of hepatocellular carcinoma patients diagnosed under regular surveillance: potential implications for surveillance goal vol.56, pp.3, 2021, https://doi.org/10.1080/00365521.2020.1866063
- Prognostic factors of gadoxetic acid-enhanced MRI for postsurgical outcomes in multicentric hepatocellular carcinoma vol.31, pp.5, 2009, https://doi.org/10.1007/s00330-020-07419-y
- Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response vol.28, pp.10, 2009, https://doi.org/10.1111/jvh.13572
- Diagnostic Performance of KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using Magnetic Resonance Imaging: A Systematic Review and Meta-Analysis vol.11, pp.10, 2009, https://doi.org/10.3390/diagnostics11101763